Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7340-7347

  Bazzaro, Martina ^a   Lin, Zhenhua ^a   Santillan, Antonio ^a,b   Lee, Michael K ^a   Wang, Mei Cheng ^b   Chan, Kwun C ^b   Bristow, Robert E ^b   Mazitschek, Ralph ^c,d   Bradner, James ^c,d,e   Roden, Richard B S ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; NK84; UBIQUITIN; UNCLASSIFIED DRUG; BORONIC ACID DERIVATIVE; ENZYME INHIBITOR; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; PROTEASOME; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL MIGRATION; CONTROLLED STUDY; DEACETYLATION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; OVARY CANCER; POLYMERIZATION; PRIORITY JOURNAL; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; METABOLISM; OVARY TUMOR; TISSUE MICROARRAY; WESTERN BLOTTING;

BLOTTING, WESTERN; BORONIC ACIDS; CELL DEATH; CELL MOVEMENT; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; OVARIAN NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TISSUE ARRAY ANALYSIS; UBIQUITIN;

EID: 58149330694     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0642     Document Type: Article

References (32)

1. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 2005;12:1178-90.
2. Aghajanian C. Clinical update: novel targets in gynecologic malignancies. Semin Oncol 2004;31:22-6; discussion 33.
3. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle 2005;4:290-6.
4. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9.
5. Bazzaro M, Lee MK, Zoso A, et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006;66:3754-63.
6. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72.
7. Pandey UB, Batlevi Y, Baehrecke EH, Taylor JP. HDAC6 at the Intersection of Autophagy, the Ubiquitin-Proteasome System and Neurodegeneration. Autophagy 2007;3:643-5.
8. Pandey UB, Nie Z, Batlevi Y, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007;447:859-63.
9. Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 2005;280:40282-92.
10. Hook SS, Orian A, Cowley SM, Eisenman RN. Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes. Proc Natl Acad Sci U S A 2002;99:13425-30.
11. Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-38.
12. Boyault C, Zhang Y, Fritah S, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007;21:2172-81.
13. Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773-81.
14. Narasipura SD, Wojciechowski JC, Charles N, Liesveld JL, King MR. P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow. Clin Chem 2008;54:77-85.
15. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronicmyelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126-35.
16. Guo F, Sigua C, Tao J, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004;64:2580-9.
17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
18. Sternson SM, Wong JC, Grozinger CM, Schreiber SL. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett 2001;3:4239-42.
19. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-34.
20. Rodriguez-Gonzalez A, Lin T, Ikeda AK, et al. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 2008;68:2557-60.
21. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994;91:8324-8.
22. Rosenwald IB. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 2004;23:3230-47.
23. Tran AD, Marmo TP, Salam AA, et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007;120:1469-79.
24. Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8.
25. Cabrero JR, Serrador JM, Barreiro O, et al. Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell 2006;17:3435-45.
26. Saji S, Kawakami M, Hayashi S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005;24:4531-9.
27. Gao YS, Hubbert CC, Lu J, et al. Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol 2007;27:8637-47.
28. Sakuma T, Uzawa K, Onda T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 2006;29:117-24.
29. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003;100:4389-94.
30. Wong JC, Hong R, Schreiber SL. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J Am Chem Soc 2003;125:5586-7.
31. Itoh Y, Suzuki T, Kouketsu A, et al. Design, synthesis, structure-selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J Med Chem 2007;22:5425-38.
32. Marcus AI, Zhou J, O'Brate A, et al. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 2005;65:3883-93.